ADAM17 and cancer: Although ADAM17 SMIs show anti‐cancer efficacy in numerous preclinical models, these inhibitors are highly toxic due to the non‐specific targeting of other metalloproteinases (e.g., ADAM10), thus highlighting the need for highly selective ADAM17 inhibitors with an alternate mode of action (Moss & Minond, 2017).